*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Mortality Rate and Survival Analysis among Hepatitis C Patients Ongoing Hemodialysis at Cempaka Putih Islamic Hospital, Jakarta – Indonesia

Author: DIANA LAILA RAMATILLAH, DIMAS PANGESTU, MAIRO HAMID IPADEOLA, AFRIANA, IHSANIL HUSNA
Abstract: The length of time a patient undergoes Hemodialysis (HD) is a factor related to the prevalence of HCV; this may be related to an increased risk of exposure to HCV in the hospital environment, such as blood transfusion, repeated vascular access, hygiene, and mixing room. So, The purpose of this research was to evaluate the mortality rate and survival analysis among hemodialyzed patients with HCV.The study was conducted by Cohort prospective and retrospective study at a hemodialysis center in Cempaka Putih Islamic Hospital Jakarta, Indonesia. Participants who were included in this study were 111 patients (mean age 53, 67% male, 33% Female). Participants of this study were HD patients with HCV who were followed up for three months and patients who had died within the last five years from 2015-2019. Universal sampling was used to select patients based on inclusion criteria. Male patients were predominant than female (64 patients). Almost all sociodemography items had a significant correlation with the duration of hemodialysis except gender (P >0,05). Around 95,65% HD patients were infected by hepatitis C after initiating hemodialysis. Most of HD patients with hepatitis C had hypertensive (63,54%) and did not receive any hepatitis C treatment (66,67%). Patients who received Daclatasvir and Sofubusvir had a 100% survival rate since the initiating of hemodialysis. The study concluded that the mortality rate was high among HCV patients undergone HD without treatment HCV, with about 8%. The highest survival rate was HD patients with hepatitis C undergoing treatment with daclatasvir + Sofosbuvir.
Keyword: Hepatitis C, Hemodialysis, Complications, Mortality Rate, Survival Rate
DOI: https://doi.org/10.31838/ijpr/2021.13.02.360
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free